503 related articles for article (PubMed ID: 18518847)
1. Failure in downregulation of intratumoral survivin expression following neoadjuvant chemoradiation in esophageal cancer.
Vallböhmer D; Kuhn E; Warnecke-Eberz U; Brabender J; Hoffmann AC; Metzger R; Baldus SE; Drebber U; Hoelscher AH; Schneider PM
Pharmacogenomics; 2008 Jun; 9(6):681-90. PubMed ID: 18518847
[TBL] [Abstract][Full Text] [Related]
2. High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer.
Xi H; Baldus SE; Warnecke-Eberz U; Brabender J; Neiss S; Metzger R; Ling FC; Dienes HP; Bollschweiler E; Moenig S; Mueller RP; Hoelscher AH; Schneider PM
Clin Cancer Res; 2005 Dec; 11(23):8341-7. PubMed ID: 16322294
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of survivin mRNA is associated with a favorable prognosis following neoadjuvant radiochemotherapy in esophageal cancer.
Warnecke-Eberz U; Hokita S; Xi H; Higashi H; Baldus SE; Metzger R; Brabender J; Bollschweiler E; Mueller RP; Dienes HP; Hoelscher AH; Schneider PM
Oncol Rep; 2005 Jun; 13(6):1241-6. PubMed ID: 15870949
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer.
Schneider S; Uchida K; Brabender J; Baldus SE; Yochim J; Danenberg KD; Salonga D; Chen P; Tsao-Wei D; Groshen S; Hoelscher AH; Schneider PM; Danenberg PV
J Am Coll Surg; 2005 Mar; 200(3):336-44. PubMed ID: 15737843
[TBL] [Abstract][Full Text] [Related]
5. Reduced incidence of nodal micrometastasis after major response to neoadjuvant chemoradiation in locally advanced esophageal cancer.
Prenzel KL; König A; Schneider PM; Schnickmann C; Baldus SE; Schröder W; Bollschweiler E; Dienes HP; Mueller RP; Izbicki JR; Hölscher AH
Ann Surg Oncol; 2007 Feb; 14(2):954-9. PubMed ID: 17103071
[TBL] [Abstract][Full Text] [Related]
6. Survivin expression in gastric cancer: Association with histomorphological response to neoadjuvant therapy and prognosis.
Vallböhmer D; Drebber U; Schneider PM; Baldus S; Bollschweiler E; Brabender J; Warnecke-Eberz U; Mönig S; Hölscher AH; Metzger R
J Surg Oncol; 2009 Jun; 99(7):409-13. PubMed ID: 19347901
[TBL] [Abstract][Full Text] [Related]
7. Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer.
Schneider PM; Metzger R; Schaefer H; Baumgarten F; Vallbohmer D; Brabender J; Wolfgarten E; Bollschweiler E; Baldus SE; Dienes HP; Hoelscher AH
Ann Surg; 2008 Dec; 248(6):902-8. PubMed ID: 19092334
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA profiling in locally advanced esophageal cancer indicates a high potential of miR-192 in prediction of multimodality therapy response.
Odenthal M; Bollschweiler E; Grimminger PP; Schröder W; Brabender J; Drebber U; Hölscher AH; Metzger R; Vallböhmer D
Int J Cancer; 2013 Nov; 133(10):2454-63. PubMed ID: 23649428
[TBL] [Abstract][Full Text] [Related]
9. [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer.
Vallböhmer D; Hölscher AH; Dietlein M; Bollschweiler E; Baldus SE; Mönig SP; Metzger R; Schicha H; Schmidt M
Ann Surg; 2009 Dec; 250(6):888-94. PubMed ID: 19953708
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemoradiation versus chemotherapy for patients undergoing esophagectomy for esophageal cancer.
Luu TD; Gaur P; Force SD; Staley CA; Mansour KA; Miller JI; Miller DL
Ann Thorac Surg; 2008 Apr; 85(4):1217-23; discussion 1223-4. PubMed ID: 18355499
[TBL] [Abstract][Full Text] [Related]
11. The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas.
Brücher BL; Becker K; Lordick F; Fink U; Sarbia M; Stein H; Busch R; Zimmermann F; Molls M; Höfler H; Siewert JR
Cancer; 2006 May; 106(10):2119-27. PubMed ID: 16607651
[TBL] [Abstract][Full Text] [Related]
12. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification.
Schneider PM; Baldus SE; Metzger R; Kocher M; Bongartz R; Bollschweiler E; Schaefer H; Thiele J; Dienes HP; Mueller RP; Hoelscher AH
Ann Surg; 2005 Nov; 242(5):684-92. PubMed ID: 16244542
[TBL] [Abstract][Full Text] [Related]
13. REG I expression predicts long-term survival among locally advanced thoracic squamous cell esophageal cancer patients treated with neoadjuvant chemoradiotherapy followed by esophagectomy.
Motoyama S; Sugiyama T; Ueno Y; Okamoto H; Takasawa S; Nanjo H; Watanabe H; Maruyama K; Okuyama M; Ogawa J
Ann Surg Oncol; 2006 Dec; 13(12):1724-31. PubMed ID: 17009160
[TBL] [Abstract][Full Text] [Related]
14. Podoplanin and SOX2 expression in esophageal squamous cell carcinoma after neoadjuvant chemo-radiotherapy.
Saigusa S; Mohri Y; Ohi M; Toiyama Y; Ishino Y; Okugawa Y; Tanaka K; Inoue Y; Kusunoki M
Oncol Rep; 2011 Nov; 26(5):1069-74. PubMed ID: 21811761
[TBL] [Abstract][Full Text] [Related]
15. ERCC1 expression and tumor regression predict survival in esophageal squamous cell carcinoma patients receiving combined trimodality therapy.
Ge H; Lu Y; Chen Y; Zheng X; Wang W; Yu J
Pathol Res Pract; 2014 Oct; 210(10):656-61. PubMed ID: 25042384
[TBL] [Abstract][Full Text] [Related]
16. Impact of ABCB1 C3435T polymorphism on lymph node regression in multimodality treatment of locally advanced esophageal cancer.
Narumiya K; Metzger R; Bollschweiler E; Alakus H; Brabender J; Drebber U; Hölscher AH; Warnecke-Eberz U
Pharmacogenomics; 2011 Feb; 12(2):205-14. PubMed ID: 21332314
[TBL] [Abstract][Full Text] [Related]
17. Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response.
Barbour AP; Jones M; Gonen M; Gotley DC; Thomas J; Thomson DB; Burmeister B; Smithers BM
Ann Surg Oncol; 2008 Oct; 15(10):2894-902. PubMed ID: 18663531
[TBL] [Abstract][Full Text] [Related]
18. Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.
Castoro C; Scarpa M; Cagol M; Ruol A; Cavallin F; Alfieri R; Zanchettin G; Rugge M; Ancona E
Ann Surg Oncol; 2011 Dec; 18(13):3743-54. PubMed ID: 21556952
[TBL] [Abstract][Full Text] [Related]
19. Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma.
Higuchi I; Yasuda T; Yano M; Doki Y; Miyata H; Tatsumi M; Fukunaga H; Takiguchi S; Fujiwara Y; Hatazawa J; Monden M
J Thorac Cardiovasc Surg; 2008 Jul; 136(1):205-12, 212.e1-3. PubMed ID: 18603077
[TBL] [Abstract][Full Text] [Related]
20. Death-associated protein kinase (DAPK) promoter methylation and response to neoadjuvant radiochemotherapy in esophageal cancer.
Brabender J; Arbab D; Huan X; Vallböhmer D; Grimminger P; Ling F; Neiss S; Bollschweiler E; Schneider PM; Hölscher AH; Metzger R
Ann Surg Oncol; 2009 May; 16(5):1378-83. PubMed ID: 19224282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
